Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Newman

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
Journal of Medicinal Chemistry|July 12, 2012
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profileFolkert Reck, Richard A Alm, Patrick Brassil, et al.
Genes & Development|March 2, 2021
Erratum: A role for alternative splicing in circadian control of exocytosis and glucose homeostasisBiliana Marcheva, Mark Perelis, Benjamin J Weidemann, et al.
Genes & Development|July 4, 2020
A role for alternative splicing in circadian control of exocytosis and glucose homeostasisBiliana Marcheva, Mark Perelis, Benjamin J Weidemann, et al.
Lancet Regional Health. Americas|September 2, 2025
Ten-year trends in opioid prescribing and vaso-occlusive crises in sickle cell disease: a population-based national cohort study (2011-2022)Kevin Y Xu, Terri V Newman, Lakeya S McGill, et al.
Nature Communications|March 14, 2025
Programmable mRNA therapeutics for controlled epigenomic modulation of single and multiplexed gene expression in diverse diseasesCharles W O'Donnell, Jeremiah D Farelli, Houda Belaghzal, et al.
Scientific Reports|September 19, 2015
Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Scientific Reports|July 15, 2015
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Bioorganic & Medicinal Chemistry|August 27, 2014
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosaFolkert Reck, David E Ehmann, Thomas J Dougherty, et al.
ACS Chemical Biology|August 23, 2012
In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compoundThomas A Keating, Joseph V Newman, Nelson B Olivier, et al.
Nature Microbiology|July 1, 2017
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiThomas F Durand-Réville, Satenig Guler, Janelle Comita-Prevoir, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
Journal of Medicinal Chemistry|July 12, 2012
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profileFolkert Reck, Richard A Alm, Patrick Brassil, et al.
Genes & Development|March 2, 2021
Erratum: A role for alternative splicing in circadian control of exocytosis and glucose homeostasisBiliana Marcheva, Mark Perelis, Benjamin J Weidemann, et al.
Genes & Development|July 4, 2020
A role for alternative splicing in circadian control of exocytosis and glucose homeostasisBiliana Marcheva, Mark Perelis, Benjamin J Weidemann, et al.
Lancet Regional Health. Americas|September 2, 2025
Ten-year trends in opioid prescribing and vaso-occlusive crises in sickle cell disease: a population-based national cohort study (2011-2022)Kevin Y Xu, Terri V Newman, Lakeya S McGill, et al.
Nature Communications|March 14, 2025
Programmable mRNA therapeutics for controlled epigenomic modulation of single and multiplexed gene expression in diverse diseasesCharles W O'Donnell, Jeremiah D Farelli, Houda Belaghzal, et al.
Scientific Reports|September 19, 2015
Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Scientific Reports|July 15, 2015
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Bioorganic & Medicinal Chemistry|August 27, 2014
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosaFolkert Reck, David E Ehmann, Thomas J Dougherty, et al.
ACS Chemical Biology|August 23, 2012
In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compoundThomas A Keating, Joseph V Newman, Nelson B Olivier, et al.
Nature Microbiology|July 1, 2017
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiThomas F Durand-Réville, Satenig Guler, Janelle Comita-Prevoir, et al.
Pageof 15